GLP-1 Cancer Prevention: Promising Research Raises Questions About Drug Access and Affordability

What Happened

Recent research presented at the American Society of Clinical Oncology (ASCO) conference suggests that GLP-1 receptor agonists—medications like semaglutide and tirzepatide used for diabetes and obesity—may also reduce cancer risk across multiple cancer types. One prominent study of over 10,000 early-stage cancer patients found GLP-1 use was associated with reduced cancer progression risk in 6 out of 7 cancers studied, with statistically significant reductions in breast, liver, colorectal, and non-small cell lung cancers. For non-small cell lung cancer specifically, the study found only 10% of GLP-1 users progressed to Stage IV disease compared to 22.3% of non-users.

Researchers hypothesize the protective effect may operate through multiple mechanisms: weight loss (obesity is a known carcinogen), plus additional anti-inflammatory and metabolic pathways in the brain and gut that the drugs influence.

Why It Matters

If validated through prospective clinical trials, GLP-1s could represent a significant shift in cancer prevention and treatment strategy. However, experts—including ASCO's chief medical officer Dr. Julie Gralow—caution that these are correlative studies based on retrospective databases that lack crucial context like patients' exercise habits, diet, comorbidities, and socioeconomic factors. The data are "far from being able to conclude that GLP-1s are effective treatments for cancer," according to the reporting.

This distinction matters enormously: correlation is not causation, and reverse causality (healthier patients may be more likely to use these drugs) cannot be ruled out from the available evidence.

Connection to CGP Policy

This research raises critical questions about pharmaceutical access and equity—areas central to the Common Good Party's vision for healthcare reform.

Drug Policy & Pricing: GLP-1 medications currently cost $900–$1,500+ per month without insurance, placing them out of reach for millions of Americans. If these drugs prove effective for cancer prevention, the current market-based system will create a two-tiered healthcare system where wealthy Americans get access to preventive cancer treatment while lower-income populations—who often face higher cancer burdens—cannot afford them. This reflects a broader CGP concern: that our drug policy prioritizes pharmaceutical industry profits over public health outcomes. The party's position on drug policy emphasizes that we've spent $1 trillion on the War on Drugs with 806,000 overdose deaths and unchanged drug use rates—a critique that extends to how we price and distribute medications broadly.

Health Equity: If GLP-1s genuinely reduce cancer risk across multiple cancer types—not just obesity-related cancers—this becomes a public health intervention, not merely a lifestyle drug. A Common Good approach would prioritize universal or subsidized access to such a preventive agent, especially for high-risk populations. Current policy leaves access to market forces.

See the full NPR article here.

Outstanding Research Questions

Critical next steps include prospective randomized controlled trials to establish causation; investigation of whether the effect holds across socioeconomic and racial groups (given disparities in both cancer incidence and obesity treatment access); and analysis of whether non-pharmacological interventions (exercise, nutrition, stress reduction) produce comparable protective effects at zero cost.